Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Multidrug resistance (MDR) significantly limits the effectiveness of cancer chemotherapy.
• Overexpression of ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (P-gp/ABCB1), is a primary cause of MDR by increasing drug efflux.
• Developing P-gp inhibitors is crucial for overcoming MDR and improving cancer treatment outcomes.

Purpose of the Study:

• To review recent advancements in the design, characterization, and mechanism of action of novel small molecule P-gp inhibitors.
• To summarize structure-activity relationship (SAR) studies of newly synthesized potent P-gp inhibitors.
• To underscore the potential of P-gp inhibitors in enhancing cancer chemotherapy efficacy.

Main Methods:

• Literature review focusing on studies published in the last 5 years.
• Analysis of drug design strategies for small molecule P-gp inhibitors.
• Evaluation of structure-activity relationship (SAR) data for newly developed inhibitors.
• Investigation of mechanisms of action for potent P-gp inhibitors.

Main Results:

• Identification of newly synthesized, potent small molecule P-gp inhibitors.
• Detailed SAR studies elucidating key structural features for P-gp inhibition.
• Characterization of the mechanisms by which these inhibitors block P-gp-mediated drug efflux.
• Progress in developing selective and non-toxic P-gp inhibitors.

Conclusions:

• Recent drug design efforts have yielded potent small molecule P-gp inhibitors.
• These inhibitors show promise in overcoming P-gp-mediated MDR in cancer.
• Further development of P-gp inhibitors will enhance our understanding of P-gp function and benefit cancer therapeutics.